Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Company Deals

Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs

Fineline Cube Jun 23, 2026
Company Deals Drug

MacroGenics Secures $24.5M Milestone from Sanofi Following FDA Approval Expansion for Tzield in Type 1 Diabetes

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody – Dual US-China Authorization for Hematological Malignancies

Fineline Cube Jun 24, 2026
Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine – First Dual-Approved Candidate Globally

Fineline Cube Jun 24, 2026
Company Deals

Fosun Pharmaceutical to Raise USD 662M via Share Issue for Drug Development and API Base

Fineline Cube Jul 22, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to issue...

Company Drug

Tris Pharma and Pediatrix’s Methylphenidate Tablet, Ipsen’s Triptorelin Injection Awarded Priority Review by CDE

Fineline Cube Jul 22, 2022

The Center for Drug Evaluation (CDE) website shows that US-based Tris Pharma and Pediatrix Therapeutics’...

Company

Roche Posts 5% H1 Sales Growth, Led by New Drugs and Immunodiagnostics

Fineline Cube Jul 22, 2022

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported a 5% year-on-year (YOY) increase in...

Company Drug

InnoCare’s Tafasitamab Receives First Prescription in China’s Bo’Ao Lecheng Pilot Zone

Fineline Cube Jul 22, 2022

China-based InnoCare (HKG: 9969) announced that the first prescription for its pipeline candidate tafasitamab (trade...

Company Deals

Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC

Fineline Cube Jul 21, 2022

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co.,...

Company Deals

MAXVAX Biotech Raises RMB500M in Series B to Advance Vaccine Pipelines

Fineline Cube Jul 21, 2022

MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9...

Company Drug

Livzon’s V-01 and V-01D-351 Vaccines Show Strong Safety, Immunity as COVID Boosters

Fineline Cube Jul 21, 2022

China-based Livzon Pharmaceutical Group (HKG: 1513) released clinical data for its recombinant novel coronavirus fusion...

Drug

CANbridge Pharmaceuticals Doses First Patient in CAN103 Gaucher Disease Trial

Fineline Cube Jul 21, 2022

China-based rare disease firm CANbridge Pharmaceuticals announced the dosing of the first patient in a...

Company Deals

InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to Advance FAK Inhibitor IN10018

Fineline Cube Jul 21, 2022

China-based biotech firm InxMed (Nanjing) Co., Ltd announced it has received $10 million in debt...

Company Deals

Frontera Therapeutics Raises $160M in Series B to Advance Gene Therapy FT-001

Fineline Cube Jul 21, 2022

Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round,...

Company Drug

DAC Biotech’s DXC005 ADC Doses First Patient in Beijing Cancer Hospital Trial

Fineline Cube Jul 20, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its...

Company

J&J Q2 Sales Rise 8% but Profits Plunge 23% Amid China COVID Lockdowns

Fineline Cube Jul 20, 2022

US giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q2 2022 financials, showing 8.0% year-on-year...

Company

Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx

Fineline Cube Jul 20, 2022

Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant...

Company Deals

Aidea Pharmaceutical Acquires 19.96% ND Pharm Stake to Boost Urokinase Business

Fineline Cube Jul 20, 2022

China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has acquired a 19.96% stake in ND...

Policy / Regulatory

NHSA Issues New Medical Service Pricing Policy to Enhance Public Welfare and Innovation

Fineline Cube Jul 20, 2022

The National Healthcare Security Administration (NHSA) has released a new notification on medical service pricing...

Company Medical Device

MicroPort CardioFlow Completes First Clinical Use of Dry Valve Transcatheter Mitral Valve System

Fineline Cube Jul 20, 2022

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company

WuXi Biologics to Build $1.4B CRDMO Hub in Singapore, Creating 1,500 Jobs

Fineline Cube Jul 20, 2022

China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...

Company Deals

Antengene and Celularity Partner on Bispecific Antibody and NK Cell Therapy Combo

Fineline Cube Jul 20, 2022

China-based Antengene Corporation Ltd (HKG: 6996) announced a preclinical partnership with U.S. firm Celularity Inc....

Drug

Kexing Pharmaceutical Launches Phase III Influenza Vaccine Study in Chile

Fineline Cube Jul 20, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced the start of a Phase III clinical trial in...

Drug

Henlius Biotech’s HLX14 Biosimilar Wins TGA Approval for Global Phase III Osteoporosis Study

Fineline Cube Jul 20, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) received approval from Australia’s Therapeutic Goods Administration (TGA)...

Posts pagination

1 … 668 669 670 … 687

Recent updates

  • Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody – Dual US-China Authorization for Hematological Malignancies
  • Ab&B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine – First Dual-Approved Candidate Globally
  • China Medical System’s Silvemimab Becomes World’s First Dual-Epitope Fully Human Rabies Antibody Approved in China
  • Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital
  • Biokin Secures World’s First EGFR×HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody – Dual US-China Authorization for Hematological Malignancies

Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine – First Dual-Approved Candidate Globally

Company Drug

China Medical System’s Silvemimab Becomes World’s First Dual-Epitope Fully Human Rabies Antibody Approved in China

Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.